PIERI, LISA

PIERI, LISA  

Medicina Sperimentale e Clinica  

Mostra records
Risultati 1 - 20 di 67 (tempo di esecuzione: 0.05 secondi).
Titolo Data di pubblicazione Autore(i) File
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 2014 F. Lussana;A. Carobbio;M. L. Randi;C. Elena;E. Rumi;G. Finazzi;I. Bertozzi;L. Pieri;M. Ruggeri;F. Palandri;N. Polverelli;E. Elli;A. Tieghi;A. Iurlo;M. Ruella;M. Cazzola;A. Rambaldi;A. M. Vannucchi;T. Barbui
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 2012 Vannucchi AM; Pieri L; Susini MC; Guglielmelli P
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 2014 Paola Guglielmelli; Giada Rotunno;Giada Brogi;Annalisa Pacilli;Costanza Bogani;Carmela Mannarelli;Alessandro Pancrazzi;Rajmonda Fjerza;Lisa Pieri;Elisa Rumi;Daniela Pietra;Federica Delaini;Silvia Salmoiraghi;Aldesia Provenzano; Laura Giunti;Sabrina Giglio;Margherita Maffioli;Alberto Bosi;Alessandro Rambaldi;Tiziano Barbui; Francesco Passamonti; Mario Cazzola and Alessandro Maria Vannucchi
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 2014 Guglielmelli, P; Rotunno, G; Brogi, G; Pacilli, A; Bogani, C; Mannarelli, C; Pancrazzi, A; Fjerza, R; Pieri, L; Rumi, E; Pietra, D; Salmoiraghi, S; Provenzano, A; Giunti, L; Giglio, S; Maffioli, M; Bosi, A; Rambaldi, A; Barbui, T; Passamonti, F; Cazzola, M; Vannucchi, Am
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 2014 Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 2014 Martinelli I;De Stefano V;Carobbio A;Randi ML;Santarossa C;Rambaldi A;Finazzi MC;Cervantes F;Arellano-Rodrigo E;Rupoli S;Canafoglia L;Tieghi A;Facchini L;Betti S;Vannucchi AM;Pieri L;Cacciola R;Cacciola E;Cortelezzi A;Iurlo A;Pogliani EM;Elli EM;Spadea A;Barbui T
Chronic myeloproliferative neoplasms: a collaborative approach. 2010 l. Pieri;P. Guglielmelli;A.M. Vannucchi
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 2014 Rumi E;Pietra D;Pascutto C;Guglielmelli P;Martinez-Trillos A;Casetti I;Colomer D;Pieri L;Pratcorona M;Rotunno G;Sant'Antonio E;Bellini M;Cavalloni C;Mannarelli C;Milanesi C;Boveri E;Ferretti V;Astori C;Rosti V;Cervantes F;Barosi G;Vannucchi AM;Cazzola M.
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 2014 Tiziana Storlazzi C;Pieri L;Paoli C;Daniele G;Lasho T;Tefferi A;Vannucchi AM
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 2013 Klampfl T;Milosevic JD;Puda A;Schönegger A;Bagienski K;Berg T;Harutyunyan AS;Gisslinger B;Rumi E;Malcovati L;Pietra D;Elena C;Della Porta MG;Pieri L;Guglielmelli P;Bock C;Doubek M;Dvorakova D;Suvajdzic N;Tomin D;Tosic N;Racil Z;Steurer M;Pavlovic S;Vannucchi AM;Cazzola M;Gisslinger H;Kralovics R
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 2011 L. Pieri; A. Spolverini;B. Scappini;U. Occhini;S. Birtolo;A. Bosi;F. Albano;C. Fava;A.M. Vannucchi
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 2017 Passamonti, F; Mora, B.; Giorgino, T.; Guglielmelli, P.; Cazzola, M.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; Cervantes, F.; Devos, T.; Palandri, F.; de Stefano, V.; Ruggeri, M.; Silver, R.; Benevolo, G.; Albano, F.; Caramazza, D.; Rumi, E.; Merli, M.; Pietra, D.; Casalone, R.; Barbui, T.; Pieri, L.; Vannucchi, A.M.
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 2016 Rotunno, Giada; Pacilli, Annalisa; Artusi, Valentina; Rumi, Elisa; Maffioli, Margherita; Delaini, Federica; Brogi, Giada; Fanelli, Tiziana; Pancrazzi, Alessandro; Pietra, Daniela; Bernardis, Isabella; Belotti, Clara; Pieri, Lisa; Sant'Antonio, Emanuela; Salmoiraghi, Silvia; Cilloni, Daniela; Rambaldi, Alessandro; Passamonti, Francesco; Barbui, Tiziano; Manfredini, Rossella; Cazzola, Mario; Tagliafico, Enrico; Vannucchi, Alessandro M; Guglielmelli, Paola
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 2010 P. Guglielmelli;F. Biamonte;A. Spolverini;L. Pieri;A. Isgrò;E. Antonioli;A. Pancrazzi;A. Bosi;G. Barosi;A.M. Vannucchi
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 2012 A.Puda;J.D. Milosevic;T. Berg;T. Klampfl;A.S. Harutyunyan;B. Gisslinger;E. Rumi;D. Pietra;L. Malcovati;C. Elena;M. Doubek;M. Steurer;N. Tosic;S. Pavlovic;P. Guglielmelli;L. Pieri;A.M. Vannucchi;H. Gisslinger;M. Cazzola;R. Kralovics.
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 2015 Tapper, William; Jones, Amy V.; Kralovics, Robert; Harutyunyan, Ashot S.; Zoi, Katerina; Leung, William; Godfrey, Anna L.; Guglielmelli, Paola; Callaway, Alison; Ward, Daniel; Aranaz, Paula; White, Helen E.; Waghorn, Katherine; Lin, Feng; Chase, Andrew; Joanna Baxter, E.; Maclean, Cathy; Nangalia, Jyoti; Chen, Edwin; Evans, Paul; Short, Michael; Jack, Andrew; Wallis, Louise; Oscier, David; Duncombe, Andrew S.; Schuh, Anna; Mead, Adam J.; Griffiths, Michael; Ewing, Joanne; Gale, Rosemary E.; Schnittger, Susanne; Haferlach, Torsten; Stegelmann, Frank; Döhner, Konstanze; Grallert, Harald; Strauch, Konstantin; Tanaka, Toshiko; Bandinelli, Stefania; Giannopoulos, Andreas; Pieri, Lisa; Mannarelli, Carmela; Gisslinger, Heinz; Barosi, Giovanni; Cazzola, Mario; Reiter, Andreas; Harrison, Claire; Campbell, Peter; Green, Anthony R.; Vannucchi, Alessandro; Cross, Nicholas C.P.
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 2011 T. Klampfl;A. Harutyunyan;T. Berg;B. Gisslinger;M. Schalling;K. Bagienski;D. Olcaydu;F. Passamonti;E. Rumi;D. Pietra;R. Jäger;L. Pieri;P. Guglielmelli; I. Iacobucci;G. Martinelli;M. Cazzola;A.M. Vannucchi;H. Gisslinger;R. Kralovics.
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 2010 Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 2012 Antonioli, E; Guglielmelli, P; Pieri, L; Finazzi, M; Rumi, E; Martinelli, V; Vianelli, N; Randi, Ml; Bertozzi, I; De Stefano, V; Za, T; Rossi, E; Ruggeri, M; Elli, E; Cacciola, R; Cacciola, E; Pogliani, E; Rodeghiero, F; Baccarani, M; Passamonti, F; Finazzi, G; Rambaldi, A; Bosi, A; Cazzola, M; Barbui, T; Vannucchi, Am
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 2009 Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM.